Figure 4

Selinexor inhibits ATC growth in vivo. (A) Immunodeficient mice received ATC cells (CAL62) subcutaneously. One week after implantation, mice began to receive either oral selinexor (10 mg/kg, 3 times per week for 4 weeks) or vehicle alone. Selinexor treatment significantly suppressed tumor volumes (mean ± SD of 6 tumors). *P ≤ 0.01; **P ≤ 0.001; ***p ≤ 0.0001(Student’s t-test). (B) Representative photograph showing decreased tumor growth in selinexor treated group compared to vehicle treated group (n = 6 for each group). Scale in cm. (Lower panel) Tumor weights from selinexor and vehicle treated groups (mean ± SD of 6 tumors, P = 0.000022). (C) At the end of the experiment, whole cell lysates (protein) were prepared from tumors resected from selinexor-treated and vehicle-treated mice and subjected to western blotting with indicated antibodies. (D and E) Tumor sections were subjected to immunohistochemical analysis. Tumors section from the selinexor-treated group showed weak staining for XPO1 (exportin 1), cell proliferation marker (Ki-67) and blood vessel marker (CD31) and strong staining for Tunel (a marker of apoptosis) as compared to vehicle-treated group original magnification, ×200; objective ×20). Columns (on the right) represent mean ± SD of three independent tumors. **P ≤ 0.001; ***p ≤ 0.0001 (Student’s t-test).